ストックスクリーナーアプリを入手
29.83
1.06%
-0.32
前日終値:
$30.15
開ける：
$30.96
24時間の取引高:
1.25M
Relative Volume:
1.05
時価総額：
$3.49B
収益：
$22.57M
当期純損益:
$-212.73M
株価収益率:
-16.53
EPS:
-1.8045
ネットキャッシュフロー:
$-142.19M
1週間 パフォーマンス:
-1.42%
1か月 パフォーマンス:
-12.62%
6か月 パフォーマンス:
-12.01%
1年 パフォーマンス:
+63.90%
1日の値動き範囲:
$29.64
$31.25
1週間の範囲:
$29.09
$31.55
52週間の値動き範囲:
$17.63
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Compare NAMS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
29.83 | 3.49B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | 開始されました | Truist | Buy |
| 2025-10-20 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-25 | 開始されました | Wells Fargo | Overweight |
| 2025-07-17 | 開始されました | Goldman | Neutral |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-06-10 | 開始されました | Stifel | Buy |
| 2025-06-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-15 | 開始されました | TD Cowen | Buy |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-01-18 | 開始されました | Guggenheim | Buy |
| 2024-01-16 | 開始されました | Piper Sandler | Overweight |
| 2023-10-30 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Newamsterdam Pharma Company Nv (NAMS) 最新ニュース
NewAmsterdam Pharma Company NV (NAMSW) Institutional Confidence - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewAmsterdam Pharma Company NV - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
The Technical Signals Behind (NAMS) That Institutions Follow - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Slides 1.26% Amidst Cautious Trading, Support at $28.7 HoldsVol Target Rebalance - newsline.com
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma Warrants (NAMSW) Plunge 11.78% as Sellers Dominate, Testing Key SupportVolume Weighted Price - newsline.com
NewAmsterdam Pharma Rises 3.17% as Shares Approach Resistance at $31.77Bollinger Band - newsline.com
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness - Yahoo Finance
(NAMSW) Risk Channels and Responsive Allocation - Stock Traders Daily
NewAmsterdam Pharma Company N.V.Ordinary Shares (NQ: NAMS - FinancialContent
EBIT of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026 - Insider Monkey
All eyes on NewAmsterdam Pharma earnings as pipeline advances - Investing.com
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
Assessing NewAmsterdam Pharma (NAMS) Valuation As New Obicetrapib Data Heads To Major Scientific Conference - Sahm
Capital World Investors holds 10.4% of NewAmsterdam Pharma (NAMS) - Stock Titan
5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller - Insider Monkey
NewAmsterdam Shareholders Approve ESPP and Governance Proposals - TipRanks
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions - The Manila Times
Oral cholesterol drug obicetrapib in multiple 2026 lipid meeting studies - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) shareholders back 2026 ESPP and extend share issuance powers - Stock Titan
(NAMSW) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Debt to assets ratio of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Inventory turnover of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
EBIT per share of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Current ratio of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Net income before discontinued operations of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Taxes of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - Sahm
NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus - Bez Kabli
NewAmsterdam Pharma (NAMS) CAO exercises options and sells 65,000 shares - Stock Titan
NewAmsterdam Pharma Warrants (NAMSW) Rally 3.05% as Price Nears Key ResistanceOvervalued Signals - thelegaladvocate.com
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
NewAmsterdam Pharma (NAMS) Edges Higher as Shares Test Key Resistance LevelArms Index - The Legal Advocate
Technical Reactions to NAMS Trends in Macro Strategies - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Q1 2026 Earnings: EPS Beat Reflects Cost Management Amid Pre-Revenue Phase - The Legal Advocate
NewAmsterdam Pharma Co NV (HAM:KH6) Cyclically Adjusted Pri - GuruFocus
NewAmsterdam Pharma (NAMS) Slightly Lower Amid Consolidation Near Key Support LevelsGamma Squeeze - newsline.com
NewAmsterdam Pharma Insiders Who Sold Avert US$477m Market Cap Dip - Moomoo
Newamsterdam Pharma Company Nv (NAMS) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):